Blow For Janssen As England's NICE Rejects Depression Spray Spravato
Draft Guidance Out For Consultation Until 18 February
Executive Summary
Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.
You may also be interested in...
Janssen May Challenge English Funding Rejection For Depression Nasal Spray
Health technology assessment body NICE has now rejected Spravato for the third time, saying it has concerns over the clinical evidence and economic model for the drug, for treating adults with major depression that is resistant to treatment.
Janssen to Address NICE's Concerns Following Another English Funding No For Spravato
UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.
Janssen’s Spravato Clears Hurdles To Secure EU Approval
Spravato has been approved for treatment-resistant depression in the EU notwithstanding last-minute objections by third parties.